A Murine Model of NKT Cell-mediated Liver Injury Induced by Alpha-galactosylceramide/d-galactosamine
Overview
Molecular Biology
Pathology
Authors
Affiliations
Natural killer-T (NKT) cells are rich in the liver. However, their involvement in liver injury is not fully understood. We developed here a new murine model of NKT-cell-activation-associated liver injury, and investigated a role of tumor necrosis factor alpha (TNF-alpha) and Fas in pathogenesis. We injected intraperitoneally alpha-galactosylceramide (alpha-GalCer), an NKT-cell stimulant, into D-galactosamine (GalN)-sensitized mice. Survival rate, pathological changes of the liver, and plasma concentrations of cytokines were studied. Alpha-GalCer/GalN administration gave a lethal effect within 7 h, making pathological changes such as massive parenchymal hemorrhage, hepatocyte apoptosis, sinusoidal endothelial cell injury, and close apposition of lymphocytes to apoptotic hepatocytes. Anti-NK1.1 mAb-pretreated mice and Valpha14NKT knock out (KO) mice did not develop liver injury. Tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) were elevated at 4 h in the plasma. These cytokines were produced by hepatic lymphocytes as demonstrated by in vitro stimulation with alpha-GalCer. The lethal effect was suppressed in TNF-alpha KO mice, TNF receptor-1 KO mice, and lpr/lpr (Fas deficient) mice, whereas it was not in IFN-gamma KO mice. These results indicate that the present liver injury is characterized by parenchymal hemorrhage and hepatocyte apoptosis, and mediated by TNF-alpha secretion and direct cytotoxicity of alpha-GalCer-activated NKT cells.
Park Y, Lee S, Kim T, Park H, Van Kaer L, Hong S Front Immunol. 2024; 15:1457690.
PMID: 39355237 PMC: 11442275. DOI: 10.3389/fimmu.2024.1457690.
Matsuo M, Kanbe A, Noguchi K, Niwa A, Imaizumi Y, Kuroda T PLoS One. 2024; 19(2):e0298284.
PMID: 38330036 PMC: 10852258. DOI: 10.1371/journal.pone.0298284.
Lee S, Park H, Van Kaer L, Hong S, Hong S Sci Rep. 2018; 8(1):10081.
PMID: 29973666 PMC: 6031608. DOI: 10.1038/s41598-018-28396-9.
Khan H, Ahmad M, Khan J, Arshad M Hepatobiliary Pancreat Dis Int. 2017; 16(3):245-256.
PMID: 28603092 PMC: 7172563. DOI: 10.1016/s1499-3872(17)60014-6.
Glucosylceramide Administration as a Vaccination Strategy in Mouse Models of Cryptococcosis.
Mor V, Farnoud A, Singh A, Rella A, Tanno H, Ishii K PLoS One. 2016; 11(4):e0153853.
PMID: 27082428 PMC: 4833283. DOI: 10.1371/journal.pone.0153853.